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Abstract
Introduction: Mesenchymal stem cell (MSC)-based therapies have had positive outcomes both in animal models of
cardiovascular diseases and in clinical patients. However, the number and function of MSCs decline during hypoxia
and serum deprivation (H/SD), reducing their ability to contribute to endogenous injury repair. MicroRNA-34a
(miR-34a) is originally identified as a TP53-targeted miRNA that modulates cell functions, including apoptosis,
proliferation, and senescence via several signaling pathways, and hence is an appealing target for MSC-based
therapy for myocardial infarction.
Methods: Bone marrow-derived MSCs were isolated from 60–80 g male donor rats. Expression levels of miR-34a
were determined by qRT-PCR. The roles of miR-34a in regulating cell vitality, apoptosis and senescence were
investigated using the cell counting kit (CCK-8) assay, flow cytometric analysis of Annexin V-FITC/PI staining and
senescence-associated β-galactosidase (SA-β-gal) staining, respectively. The expression of silent information
regulator 1 (SIRT1) and forkhead box class O 3a (FOXO3a) and of apoptosis- and senescence-associated proteins in
MSCs were analyzed by western blotting.
Results: The results of the current study showed that miR-34a was significantly up-regulated under H/SD
conditions in MSCs, while overexpression of miR-34a was significantly associated with increased apoptosis, impaired
cell vitality and aggravated senescence. Moreover, we found that the mechanism underlying the proapoptotic
function of miR-34a involves activation of the SIRT1/FOXO3a pathway, mitochondrial dysfunction and finally,
activation of the intrinsic apoptosis pathway. Further study showed that miR-34a can also aggravate MSC
senescence, an effect which was partly abolished by the reactive oxygen species (ROS) scavenger, N-acetylcysteine
(NAC).
Conclusions: Our study demonstrates for the first time that miR-34a plays pro-apoptotic and pro-senescence roles
in MSCs by targeting SIRT1. Thus, inhibition of miR-34a might have important therapeutic implications in
MSC-based therapy for myocardial infarction.
Introduction
Ischemic heart disease (IHD) is the leading cause of
death worldwide, and the resulting heart failure aggra-
vates a country’s health burden, particularly in developed
countries [1]. Existing therapies are typically only able to
slow, rather than reverse or prevent, the progression of
heart failure. Furthermore, side effects remain the key
issue among these effective therapeutics [2]. In the last
few years, bone marrow-derived mesenchymal stem cells
(MSCs) have been found to function as one of the most
suitable candidate seed cells for repairing and regenerat-
ing cardiomyocytes as well as restoring heart function,
and have been widely studied [3, 4]. Transplantation of
MSCs leads to improved neovascularization of ischemic
myocardium and inhibition of myocardial fibrosis, in
addition to an increase in the secretion of prosurvival
growth factors, including vascular endothelial growth
factor, insulin-like growth factor, and hepatocyte growth
factor [4, 5]. Despite these advantages, the poor survival
rate of MSCs within the first few days after engrafting in
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infarcted hearts leads to only marginal functional im-
provement [6, 7]. The harsh microenvironment of the
infarcted myocardium produces high levels of oxidative
stress, which makes a great contribution to cellular sen-
escence and causes a sharp decline in the proliferative
capacity and regenerative potential of MSCs [8]. There is
thus an urgent need to identify a strategy to protect the
cells against the hostile microenvironment created by
ischemia, hypoxia, the inflammatory response, and
pro-apoptotic and pro-senescence factors in order to
improve the efficacy of MSC transplantation therapy.
MicroRNAs (miRNAs) are endogenous ~22-nucleotide
RNAs that have emerged as negative regulators of gene
expression, acting by targeting mRNAs for cleavage or
translational repression, which occurs primarily through
base pairing to the 3′ untranslated regions (UTRs) of
target mRNAs [9, 10]. With rapid advances in under-
standing of the regulation and roles of these small, non-
coding RNAs in cardiac pathology, the therapeutic
potential of regulation of miRNAs in cardiac disease set-
tings is considered high [9, 11]. Among the known miR-
NAs, expression of miR-34a was found to be elevated in
mouse hearts after myocardial infarction (MI) [12] and
in cardiac tissue from patients with heart disease [13],
while inhibition of the expression of miR-34a alleviated
apoptosis and senescence in myocardial cells [14, 15]
and other cell lines [16–18]. However, the precise role of
miR-34a in MSCs has not been unraveled to date.
Silent information regulator 1 (SIRT1), one of the po-
tential targets of miR-34a [19], is an NAD-dependent dea-
cetylase that regulates apoptosis in response to oxidative
and genotoxic stress and plays a critical role in regulating
cell cycle, senescence, and metabolism [19–21]. Initially
identified as a longevity gene, SIRT1 has recently been im-
plicated as a novel modulator of myocyte homeostasis,
playing a key role in cardiomyopathy through the
deacetylation of forkhead box O transcription factor
3a (FOXO3a) [20], which was also acknowledged as the
transcription factor most closely related to the anti-
oxidative protective effects associated with longevity [22,
23]. Further study showed in endothelial progenitor cells
(EPCs) that SIRT1 has a pivotally protective role in the
regulation of EPC apoptosis induced by H2O2, and that
SIRT1 exerted this protective effect by inhibiting FOXO3a
via FOXO3a ubiquitination and subsequent degradation
[24]. However, it is entirely unknown whether SIRT1 af-
fects biological activities in MSCs; and if so, what role
FOXO3a plays in this process.
In the current study, we tested the hypothesis that
overexpression of miR-34a increases cellular susceptibil-
ity to hypoxia and serum deprivation (H/SD)-induced
apoptosis and aggravates cell senescence, and investi-
gated the underlying mechanisms. The results showed
that miR-34a played a crucial role in a plethora of
biological processes via regulation of SIRT1/FOXO3a
and the reactive oxygen species (ROS) pathway in MSCs.
Inhibition of miR-34a might therefore be a promising
therapeutic strategy for enhancing the biological func-
tions of MSCs, thus demonstrating great therapeutic po-
tential in clinical transplantation.
Materials and methods
Ethics statement
Male Sprague–Dawley rats weighing 60–80 g were ob-
tained from the Laboratory Animal Science Department
of the Second Affiliated Hospital of Harbin Medical
University, Heilongjiang, P.R. China. All experimental
animal procedures were approved by the Local Ethical
Committee on Animal Care and Use of Harbin Medical
University.
MSC culture
MSCs were cultured using the whole bone marrow ad-
herent method, as described previously [25]. Briefly, total
bone marrow was harvested from the femora of rats and
was plated into 25 cm2 culture flasks at a concentration
of 106 cells/ml in Iscove’s modified Dulbecco’s medium
(IMDM; HyClone-Thermo Fisher Scientific, Waltham,
MA, USA) supplemented with 10 % fetal bovine serum
(FBS; Gibco, Grand Island, NY, USA) and 1 % penicillin/
streptomycin (Beyotime Institute of Biotechnology,
Nantong, China), at 37 °C with 5 % CO2. After 3 days
of incubation, the medium was changed and then re-
placed every 3 days thereafter. Approximately 7–9 days
after seeding, the cells became 70–80 % confluent. The
adherent cells were released from the dishes using
0.25 % trypsin (Beyotime Institute of Biotechnology,
Beijing, China) and expanded at a 1:2 or 1:3 dilution.
MSCs at passage 3–5 were used in all experiments.
MSCs were characterized by flow cytometric analysis
for the expression of the typical markers CD90, CD29,
and CD44 (all from BD Biosciences, Franklin Lakes,
NJ, USA), and the absence of the hematopoietic
markers CD45 (eBioscience, San Diego, CA, USA) and
CD34 (Santa Cruz Biotechnology, Inc., Dallas, TX,
USA), as reported previously [25].
Cell viability assay
The viability of MSCs was determined using the cell
counting kit-8 (CCK-8) assay (Beyotime Institute of Bio-
technology, Beijing, China) in accordance with the man-
ufacturer’s protocols. Cells were seeded into a 96-well
plate (3000 cells per well), and their growth was mea-
sured following addition of 10 μl CCK-8 into the culture
medium for 2 hours. The absorbance of each well was
quantified at 450 nm (Tecan Infinite M200 microplate
reader; LabX, Austria). All data were calculated from
triplicate samples.
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MSC H/SD treatment
Apoptosis was induced by H/SD in vitro, which was de-
signed to mimic the in vivo conditions of ischemia in
the myocardium and was carried out as reported previ-
ously [26]. Briefly, MSCs were washed and cultured with
serum-free IMDM and incubated in a 5 % CO2/95 % N2
incubator (controlled atmosphere chamber; PLAS-Labs,
Lansing, MI, USA) for 6 hours. MSCs incubated in a
5 % CO2/95 % O2 incubator were used as the normoxic
control and cultured in complete medium.
Measurement of apoptosis
Apoptosis was determined by staining cells with Annexin
V–fluorescein isothiocyanate (FITC) and counterstaining
with propidium iodide (PI) using the Annexin V–FITC/PI
apoptosis detection kit (BD PharMingen, San Diego, CA,
USA). Briefly, 0.5 × 106 cells were washed twice with
phosphate-buffered saline (PBS) and stained with 5 μl
Annexin V–FITC and 5 μl PI in 1× binding buffer (BD
PharMingen) for 15 minutes at room temperature in the
dark. Analyses were performed using bivariate flow cytome-
try in a BD FACSCanto II equipped with BD FACSDiva
software (Becton-Dickinson, San Jose, CA, USA).
Target gene prediction
To identify the potential targets of miR-34a that medi-
ated its pro-apoptotic role in MSCs, bioinformatics algo-
rithms including miRBase (University of Manchester,
Manchester, UK), TargetScan (David Bartel Lab,
Whitehead Institute for Biomedical Research, MA, USA),
PicTar (Rajewsky lab, NY, USA and Max Delbruck
Centrum, Berlin, DE), and miRanda (Computational
Biology Center at MSKCC, NY, USA) were applied.
Cell transfection
Before transfection, MSCs were replanted into six-well
plates at a density of 2 × 105 cells per well and incubated
overnight. For overexpression or inhibition of miR-34a,
cells were transfected with different concentrations of
miR-34a mimic or miR-34a inhibitor (both from Invi-
trogen, Carlsbad, CA, USA). For small interfering RNA
(siRNA)-mediated gene knockdown, 100 nM SIRT1
siRNA (GenePharma Co., Ltd, Shanghai, China) was
transfected into cells. As controls, cells were trans-
fected with negative control (NC) mimic, NC inhibitor
of miR-34a (both from Invitrogen,Carlsbad, CA, USA),
or scrambled siRNA (siRNA-NT) of SIRT1 (Gene-
Pharma Co., Ltd, Shanghai, China). All miRNAs and
siRNA were transfected into MSCs using a commercial
transfection reagent (X-treme siRNA Transfection
Reagent; Roche Applied Science, Penzberg, Germany)
according to the manufacturer’s protocol. Forty-eight
or 72 hours after transfection, cells were harvested
for further analysis.
RNA extraction and quantitative RT-PCR
For analysis of miR-34a expression, total RNA was extracted
from the MSCs using TRizol reagent (Invitrogen, Shanghai,
China) and reverse-transcribed into cDNA according to the
manufacturer’s instructions. Quantitative RT-PCR (qRT-
PCR) was performed to analyze the level of miR-34a with
the miRcute miRNA First-Strand cDNA Synthesis Kit and
the miRcute miRNA qPCR Detection Kit (SYBR Green;
Tiangen, Beijing, China). All primers for miR-34a and U6
for the TaqMan miRNA assays were purchased from Gene
Pharma. Relative gene expression levels were calculated by
comparing the △Ct values between control and experimental
conditions for each PCR target using the following equation:
Relative gene expression ¼ 2‐ ΔCt sample‐ΔCT controlð Þ:
For several other genes, total cellular RNA was isolated and
reverse-transcribed using the transcriptor First-Stand cDNA
Synthesis Kit, according to the manufacturer’s instructions.
qRT-PCR was carried out using the fast-start universal SYBR
master and fluorescence quantitative PCR system [27]. The
relative expression level of mRNAs was normalized to that of
the internal control glyceraldehyde 3-phosphate dehydrogen-
ase (GAPDH) using the 2–ΔΔCt cycle threshold method.
Table 1 presents all related gene sequences.
Measurement of mitochondrial membrane potential
Mitochondrial membrane potential (ΔΨm) was mea-
sured using the JC-1 mitochondrial membrane potential
assay kit (Beyotime Institute of Biotechnology, Beijing,
China). JC-1 was widely used to assess changes in ΔΨm
and mitochondrial permeability transition. After desig-
nated treatment, cells were incubated with JC-1 working
dye for 20 minutes, then washed twice with cold JC-1
staining buffer and visualized under a fluorescence micro-
scope (DMI4000B; Leica, Wetzlar, Germany).
ROS staining
Cells were left untreated or pretreated with NAC, miR-34a
mimic, siRNA-SIRT1, and miR-34a inhibitor separately or
in combination and then stimulated with the diluted fluor-
oprobe 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-
DA; Beyotime Institute of Biotechnology, Beijing, China)
for 20 minutes at 37 °C with slight shaking every 5 minutes.
After washing with serum-free culture medium, the cells
were collected and examined by flow cytometry.
Senescence-associated β-galactosidase staining
MSC senescence was determined by in situ staining for
senescence-associated β-galactosidase (SA-β-gal) using
a senescence cell histochemical staining kit (Beyotime
Institute of Biotechnology, Beijing, China). Briefly,
MSCs after treatment were first fixed for 30 minutes at
room temperature in fixation buffer. After washing with
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PBS, cells were incubated with β-galactosidase staining so-
lution for 16 hours at 37 °C without CO2. The reaction
was stopped by the addition of PBS. Statistical analysis
was performed by counting 600 cells for each sample.
Protein extraction and western blot analysis
After designated treatment, cells were washed twice with
ice-cold PBS, and the total protein concentration was ana-
lyzed using the bicinchoninic acid assay (BCA; Beyotime In-
stitute of Biotechnology, Beijing, China) according to the
manufacturer’s instructions. Total cell extracts (50 μg total
protein) were resolved by sodium dodecyl sulfate (SDS)–
10 % polyacrylamide gel electrophoresis and transferred
onto polyvinylidene difluoride (PVDF) membranes. Non-
specific binding was inhibited by incubating the mem-
branes with 8 % skimmed milk in Tris-buffered saline
(TBS) with 0.5 % Tween-20. Subsequently, membranes
were incubated with antibodies against SIRT1, FOXO3a,
cleaved-caspase 3 (Cl.CASP3), cleaved-polyADP-ribose
polymerase 1 (Cl.PARP1), cytochrome c, P53 (all from Cell
Signaling Technology, Danvers, MA, USA), p16, γ-H2A.X
(both from Abcam, Cambridge, MA, USA), p21 (Santa
Cruz, CA, USA), and β-actin (Zhongshan Golden Bridge
Biotechnology, Beijing, China) overnight at 4 °C at an ap-
propriate dilution (1:1000). The membranes were washed
withTBS withTween-20 (TBS-T) and then incubated with
peroxidase-conjugated Affinipure goat anti-rabbit IgG
(H + L) and anti-mouse IgG (H + L)-labeled secondary
antibodies (Zhongshan Golden Bridge Biotechnology,
Beijing, China) diluted at 1:5000 for 1 hour at 37 °C. Specific
complexes were visualized on an X-ray film using Electro-
Chemi-Luminescence (ECL) detection with BeyoECL Plus
(Beyotime Institute of Biotechnology, Beijing, China) fol-
lowing the manufacturer’s protocol. All data were ob-
tained in triplicate, independent experiments.
Statistical analysis
All data were analyzed using SPSS 19.0 (SPSS Inc., Chicago, IL,
USA) and were expressed as mean± standard deviation (SD).
Comparisons between two groups were performed using Stu-
dent’s t test, while the significance of differences between three
ormore experimental groups was determined by one-way ana-
lysis of variance.P<0.05was considered statistically significant.
Results
miR-34a expression increases under H/SD, and correlates
with decreased cell survival and increased apoptosis
qRT-PCR results showed that miR-34a was expressed in
normal MSCs and that expression increased significantly
when exposed to atmospheric conditions representing
H/SD for 6 hours (Fig. 1a). We then used CCK-8 to
evaluate the role of miR-34a in MSC survival, and found
that overexpression of miR-34a reduced cell survival,
while inhibition of miR-34a expression showed the op-
posite effect (Fig. 1b, c). Apoptosis has been identified as
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FOXO3a forkhead box O transcription factor 3a, miRNA microRNA, NC negative control, siRNA small interfering RNA, siRNA-NT scrambled siRNA, SIRT1 silent
information regulator 1
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a major mechanism that reduces the survival rate after
transplantation of MSCs into the harsh microenviron-
ment of infarcted myocardium [26, 28]. To further de-
termine the role of miR-34a in MSCs under conditions
of H/SD, Annexin V–FITC/PI staining was performed.
The results showed that miR-34a mimic-treated MSCs
were significantly more apoptotic than the NC mimic
group both in normal and H/SD conditions (Fig. 1d, e).
However, when miR-34a was inhibited, MSCs showed
better resistance to H/SD than the NC inhibitor group
(Fig. 1d, e). This supports our hypothesis that the de-
creased cell survival and increased apoptosis in MSCs
are associated with overexpression of miR-34a.
SIRT1 is a direct target of posttranscriptional repression
by miR-34a
Bioinformatics results suggested that SIRT1, identified
as an apoptosis-associated gene, was the potential target
of miR-34a. In addition, miRBase showed that the bind-
ing sites of miR-34a are evolutionarily conserved in both
human and mouse (Fig. 2a). To test the hypothesis that
miR-34a regulates SIRT1 expression in MSCs from rats,
we transfected MSCs with a miR-34a mimic or miR-34a in-
hibitor. As a control, some cells were transfected with NC
mimic or NC inhibitor. Western blot analysis demonstrated
a dose-dependent decrease in SIRT1 protein expression in
miR-34a mimic-transfected cells compared with the NC
mimic group (Fig. 2c). Notably, the inhibition of miR-34a in
MSCs was concurrent with the increased expression of
SIRT1 (Fig. 2d). However, qRT-PCR showed little difference
in the expression levels of SIRT1 mRNA among the treat-
ment groups. These data suggest that SIRT1 is likely to be
targeted by miR-34a posttranscriptionally.
miR-34a induces apoptosis by modifying SIRT1 and
FOXO3a expression
After identifying SIRT1 as a direct target of miR-34a, we
investigated whether knockdown of SIRT1 by siRNA
(siRNA-SIRT1) induces apoptosis in MSCs. Similar to
miR-34a mimic treatment, suppression of SIRT1 expres-
sion promoted apoptosis, revealed by flow cytometric
Fig. 1 miR-34a expression increases under H/SD, and correlates with decreased cell survival and increased apoptosis. a Rat MSCs were cultured in
normal condition or exposed to H/SD for 6 hours and were transiently transfected with miR-34a mimic, NC mimic, miR-34a inhibitor, or NC
inhibitor for 48 hours, respectively. The expression of miR-34a was determined by qRT-PCR. *P <0.05. b, c Effects of miR-34a on the vitality of MSCs
were examined by CCK-8 assay. *P <0.05 vs. NC mimic (b), *P <0.05 vs. NC inhibitor (c). d, e Flow cytometric analysis of apoptotic cells in normal
and H/SD conditions, in cultures of miR-34a mimic, NC mimic, miR-34a inhibitor, or NC inhibitor treated (MSCs were transfected for 48 hours and
exposure to H/SD and maintained as such for 6 hours). Each column represents mean ± SD from three independent experiments. *P <0.05. H/SD
hypoxia and serum deprivation, miRNA microRNA, NC negative control, PI propidium iodide
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analysis of the percentage of cells that were Annexin V
+/PI– (Fig. 3a, b). CASP3 is a well-studied mediator of
apoptosis, because it is either partially or totally respon-
sible for the cleavage of many key proteins, such as
PARP1 [18]. In this study, increased activities of the
cleaved CASP3 and cleaved PARP1 were observed when
SIRT1 was knocked down or miR-34a was overexpressed
(Fig. 3b, d). These findings suggest that knockdown of
SIRT1 or treatment with miR-34a mimic acts similarly
in the regulation of apoptosis.
To further elaborate the relationship between miR-34a
and SIRT1, MSCs were transfected with miR-34a inhibi-
tor or siRNA-SIRT1, or a combination, before exposure
to H/SD. The results showed miR-34a inhibitor reduced
CASP3 activity and expression of cleaved PARP1 (Fig. 3e,
f ), while siRNA-SIRT1 partly abolished the effects of the
miR-34a inhibitor, verified both by flow cytometric ana-
lysis of the percentage of Annexin V+/PI– cells (Fig. 3a,
b) and by western blot analysis of cleaved CASP3 and
cleaved PARP1 (Fig. 3e, f ).
SIRT1 plays important roles in many pathophysiological
processes by deacetylating various substrates, including
FOXO3, which has been reported to promote apoptosis by
regulating its downstream target, the well-known pro-
apoptotic protein Bim [24]. Our work revealed that downreg-
ulation of miR-34a decreased total FOXO3a and Bim protein
expression, whereas SIRT1 knockdown increased the expres-
sion of these two proteins (Fig. 3e, f). However, neither miR-
34a inhibitor nor siRNA-SIRT1 altered the mRNA level of
FOXO3a (data not shown), indicating that miR-34a and
SIRT1 could regulate FOXO3a posttranscriptional activity
under H/SD conditions. Our study revealed that the activa-
tion of SIRT1/FOXO3a and the intrinsic apoptosis pathway
of CASP3–PARP1 might be involved in the pro-apoptotic
function ofmiR-34a.
miR-34a exerts pro-apoptotic effects via activation of the
mitochondrial apoptosis pathway
ΔΨm is the main parameter of mitochondrial function
used as an indicator of cell health [29]. Therefore, to
Fig. 2 SIRT1 is a direct target of posttranscriptional repression by miR-34a. a The predicted targeting sites with miR-34a of SIRT1 3′-UTR (Hsa,
human; Mmu, mouse) are highlighted in red. b qRT-PCR analysis was applied to detect mRNA expression of SIRT1 in MSCs after transfection with
miR-34a mimic, NC mimic, miR-34a inhibitor, or NC inhibitor for 48 hours, respectively. c, d Western blot analysis showed dose-dependent
regulation of SIRT1 by miR-34a after transfection with miR-34a mimic, NC mimic, miR-34a inhibitor, or NC inhibitor for 72 hours, respectively. Each
column represents mean ± SD from three independent experiments. *P <0.05 vs. control, △P <0.05 vs. transfection with 10 nM miR-34a mimic.
miRNA microRNA, NC negative control, ORF open reading frame, SIRT1 silent information regulator 1, UTR untranslated region
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Fig. 3 miR-34a induces apoptosis by modifying SIRT1 and FOXO3a expression. a, b Apoptosis was analyzed by measuring Annexin V+/PI– cells
using flow cytometry in cultures of siRNA-SIRT1, siRNA-NT, or siRNA-SIRT1 cotransfected with miR-34a inhibitor-treated MSCs, under normal and
H/SD conditions (MSCs were transfected for 72 hours and exposure to H/SD and maintained as such for 6 hours). *P <0.05 vs. normal siRNA-NT,
△P < 0.05 vs. H/SD siRNA-NT. c, d MSCs were transfected with miR-34a mimic, NC mimic, siRNA-SIRT1, or siRNA-NT for 72 hours, respectively, and
then CASP3 and PARP1 activity was measured using western blot. *P <0.05 vs. NC mimic, △P <0.05 vs. siRNA-NT. e, f Western blot analysis of
SIRT1, FOXO3a, Bim, CASP3, and PARP1 protein expression in cultures of siRNA-NT, siRNA-SIRT1, miR-34a inhibitor, or siRNA-SIRT1 cotransfected
with miR-34a inhibitor-treated MSCs, under normal and H/SD conditions (MSCs were transfected for 72 hours and exposure to H/SD and
maintained as such for 6 hours). β-actin was used as the internal control. Each column represents mean ± SD from three independent experiments.
*P <0.05 vs. normal scramble, △P <0.05 vs. H/SD scramble. CASP3 caspase 3, FOXO3a forkhead box O transcription factor 3a, H/SD hypoxia and serum
deprivation, miRNA microRNA, NC negative control, PARP1 polyADP-ribose polymerase 1, PI propidium iodide, SIRT1 silent information regulator 1, siRNA
small interfering RNA, siRNA-NT scrambled siRNA
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understand the intrinsic apoptotic pathway that is acti-
vated by miR-34a, we performed JC-1 staining. In con-
trast to the scramble cells, cells treated with the miR-34a
inhibitor displayed significant changes in ΔΨm (Fig. 4a).
To further ascertain the effect of miR-34a, cellular frac-
tionation was performed and cell lysates from cytosolic
and mitochondrial fractions were subjected to western
blotting to detect the expression of cytochrome c, which
was released from mitochondria and functioned as a key
mediator of apoptosis [30]. Western blot analysis re-
vealed an inhibition of cytochrome c release in the miR-
34a inhibitor group, while siRNA-SIRT1 reversed its ef-
fect (Fig. 4b, c). Taken together, these data support the
hypothesis that miR-34a may be involved in the apop-
totic process of MSCs induced by H/SD through activa-
tion of the mitochondrial apoptosis pathway by targeting
SIRT1.
Overexpression of miR-34a induces senescence in MSCs
Considering that the regenerative capacity of MSCs con-
tributed greatly to their function, we further examined
cellular senescence in miR-34a mimic-transfected MSCs.
SA-β-gal activity, which is a characteristic feature of
senescence-related growth arrest [31], was assayed. Re-
sults revealed that overexpression of miR-34a signifi-
cantly increased the percentage of SA-β-gal-positive
cells compared with that of scramble (Fig. 5a, b). SIRT1
inhibition has been reported to be associated with
premature senescence and impaired proliferative activity
in EPCs [17]. Consistently, the percentage of SA-β-gal-
positive senescent cells was remarkably increased follow-
ing SIRT1 knockdown (Fig. 5a, b).
ROS have been reported to induce oxidative stress that
causes DNA and cell damage and can induce cell senes-
cence through the p53/p21 pathway [32]. As expected, the
miR-34a mimic increased ROS production, which was al-
leviated by addition of the ROS scavenger N-acetylcysteine
(NAC) (Fig. 5c, d). γ-H2A.X, a sensitive marker for the
formation of DNA damage foci, was examined by western
blotting together with the senescence-related proteins
p53, p21, and p16. In the miR-34a mimic and siRNA-
SIRT1 group, the expression of p16, p53, and p21 was ob-
viously increased compared with that in the control group
(Fig. 5e, f). However, when ROS was removed by NAC or
when miR-34a was inhibited by a miR-34a inhibitor, the
expression of γ-H2A.X, p16, p53, and p21 was signifi-
cantly reduced (Fig. 5e, f ).
Discussion
Our results show that miR-34a is significantly upregu-
lated under H/SD conditions in MSCs, and overexpres-
sion of miR-34a is strongly associated with increased
apoptosis, lower viability, and increased senescence.
SIRT1, identified as a direct and functional target of
miR-34a, protects MSCs from H/SD-induced apoptosis
through its downstream effector FOXO3a. Further
Fig. 4 miR-34a exerts pro-apoptotic effects via activation of the mitochondrial apoptosis pathway. MSCs were transfected with siRNA-NT, siRNA-
SIRT1, miR-34a inhibitor, or siRNA-SIRT1 cotransfected with miR-34a inhibitor under normal and H/SD conditions (MSCs were transfected for
72 hours and exposure to H/SD and maintained as such for 6 hours). Then ΔΨm (a) was analyzed by measuring JC-1 fluorescence, and cytosolic
and mitochondrial cytochrome c expression (b, c) were measured with western blot. Each column represents mean ± SD from three independent
experiments. *P <0.05 vs. H/SD scramble, △P <0.05 vs. miR-34a inhibitor,▲P <0.05 vs. siRNA-SIRT1. H/SD hypoxia and serum deprivation, miRNA
microRNA, SIRT1 silent information regulator 1, siRNA small interfering RNA
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experiments indicated that the mitochondrial permeabil-
ity transition and intrinsic apoptosis pathway of the
CASP3–PARP1 axis were involved during this process.
Moreover, miR-34a was also found to aggravate the sen-
escence of MSCs in a ROS-dependent manner. This
study strongly suggests that miR-34a is a promising can-
didate for a more optimized and appealing target for
MSC-based therapy in MI.
Since MSCs are easily obtained and exhibit impressive
paracrine ability as well as multilineage differentiation
potential [33], autologous MSCs offer a great advantage
when transplanted into ischemic or infarcted heart to re-
generate and repopulate the injured myocardium and re-
store heart function. However, repair of cardiomyocytes
and restoration of heart function are limited by poor
survival [34], increased senescence [35], and loss of
Fig. 5 Overexpression of miR-34a induces senescence in MSCs. Cells were left untreated or pretreated with miR-34a mimic, siRNA-SIRT1, ROS
scavenger NAC (10 mM), and miR-34a inhibitor separately or in combination for 72 hours, and then cellular senescence was analyzed by SA-β-gal
staining (a, b). Cellular ROS production was assessed by measuring the fluorescent intensity of DCFH-DA determined using flow cytometry (c, d).
Cellular DNA damage and senescence-related proteins including γ-H2A.X, p53, p21, and p16 were determined with western blot (e, f). Each
column represents mean ± SD from three independent experiments. *P <0.05 vs. scramble, △P <0.05 vs. miR-34a mimic,▲P <0.05 vs. siRNA-SIRT1.cp.
DCFH 2′,7′-dichlorodihydrofluorescein, MFI mean fluorescence intensity, miRNA microRNA, NAC N-acetylcysteine, SA-β-gal senescence-associated
galactosidase, SIRT1 silent information regulator 1, siRNA small interfering RNA
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immunoprivilege in long-term preclinical studies of
engrafted MSCs in the infarcted area [36]. Researchers
have attempted numerous approaches to overcome these
limitations, and have made some improvements in re-
storing cardiac function [37, 38]. Despite these suc-
cesses, strategies are still needed to make transplanting
MSCs into the infarcted area easier and more effective.
Recent observations have revealed that miRNAs are
involved in the processes of apoptosis, proliferation, sen-
escence, autophagy, and differentiation, among others,
exhibiting powerful and unexpected roles in modulating
cell biological functions by upregulating or downregulat-
ing these processes [18, 39]. Among the known miRNAs,
miR-34a has been demonstrated to be involved in apop-
tosis [40] and senescence [17] and to inhibit various key
regulators of cell cycle progression [41]. miR-34a be-
longs to one of several evolutionarily-conserved families
of miRNAs, namely miR-34, and was originally identified
as a TP53-targeted mRNA [40]. miR-34a was expressed
in almost every tissue but was scarcely expressed in lung
tissue [42]. Frequently downregulated and functioning as
an independent prognostic indicator in multiple types of
cancers [18, 43], miR-34a expression levels were signifi-
cantly upregulated in the animal model of acute MI and
in the aged hearts [15] and were strongly correlated with
left ventricular end-diastolic dimension 1 year after
acute MI [44]. Furthermore, overexpression of miR-34a
was demonstrated to promote the apoptosis of myocar-
dial cell during MI [45], aggravate senescence, and im-
pede angiogenesis ability of EPCs [17] and endothelial
cells [46], as well as induce senescence and inflammation
in vascular smooth muscle cells [47], leading to myocar-
dial and vascular dysfunctions. Delivery of antagomir
Ant-34a or LNA-based anti-miRNAs, however, en-
hanced cardiac contractile recovery after acute MI,
which was associated with reduced fibrosis, increased ca-
pillary density, and elevated myocardial cell functions
[14, 15]. Thus, we presumed that miR-34a may play a
crucial role in the MI microenvironment and contribute
to the poor survival rate of MSCs in the infarcted area.
In the present study, we showed that miR-34a was
expressed in normal MSCs and was elevated greatly dur-
ing H/SD, designed to mimic the in vivo conditions of
ischemia and hypoxia. Overexpression of miR-34a aggra-
vated MSC apoptosis, while inhibition of miR-34a expres-
sion conferred resistance to H/SD-induced apoptosis.
These data suggests that miR-34a not only regulates resi-
dent myocardial cell apoptosis but also plays an important
role in engrafted MSCs survival in the infarcted area.
SIRT1, one of the potential targets of miR-34a, has
been identified as an apoptosis inhibitor and has been
found to act as a longevity gene in many studies re-
ported previously [48]. Recently, SIRT1 was reported to
inhibit the apoptosis of vascular adventitial fibroblasts
(VAFs) [49]. Consistent with this report, our results
showed that when SIRT1 was knocked down by siRNA-
SIRT1, the apoptosis of MSCs induced by H/SD in-
creased. However, we found a moderate increase in the
expression of SIRT1 protein level in MSCs during H/SD
(Fig. 3e), which was also found in EPCs exposed to
H2O2 [24]. As is well known, SIRT1 is an NAD-
dependent deacetylase, and the balance between NAD
+/NADH is crucial for cellular survival. A recent study
demonstrated that during hypoxic and ischemic insults
the concentration of NAD+ increases at the very begin-
ning, leading to activation of the SIRT1-dependent
cleavage of acetyl groups [50]. This compensation effect
can partly explain our result of the increased SIRT1 ex-
pression during H/SD.
In response to oxidative stress, SIRT1 forms a complex
with FOXO3 and then enhances cellular stress resistance
[51]. FOXO3a is a member of the mammalian FOXO
family of forkhead transcription factors, which are crit-
ical regulators of stress responses, oncogenesis, and lon-
gevity by directly regulating the genes involved in
apoptosis, cell cycle progression, and stress responses
[52]. FOXO activities can be regulated by phosphoryl-
ation, ubiquitination, as well as deacetylation to inhibit
apoptosis [25, 51, 53]. It has been identified that SIRT1
can bind to and deacetylate FOXO3a and then suppress
its transcriptional activity, which also exerts favorable ef-
fects on oxidative stress resistance in cardiac myocytes
[51]. In the current study, we showed in MSCs that
FOXO3a was downregulated in response to a miR-34a
inhibitor, and could be abolished by silencing SIRT1 ex-
pression, suggesting that the restorative function of the
miR-34a inhibitor in MSCs was mediated through the
SIRT1–FOXO3a signaling pathway. Regulation of the
SIRT1–FOXO3a signaling pathway through some basic
strategies may therefore play an active role in clinical
heart disease.
We further examined the role of ΔΨm and the intrin-
sic apoptosis pathway of the CASP3–PARP1 axis in the
pro-apoptotic activity of miR-34a in MSCs. Considerable
evidence implicated that mitochondrial dysfunction or a
change in the ΔΨm was one of the signs of cell death
[28]. The decrease of ΔΨm activates effector CASP3 by
a series of reactions, and subsequently induces cell apop-
tosis. As expected, we found that inhibition of miR-34a
increased the ΔΨm of MSCs during H/SD, and de-
creased cleaved CASP3 expression.
Like other cells, MSCs entered into the senescence
process when exposed to oxidative stress which greatly
reduced their regenerative capacity and limited their
transplantation efficiency. As an inevitable by-product of
mitochondrial respiration, ROS in moderate amounts is
necessary for cell survival, proliferation, and longevity
[54]. However, during hypoxia, an imbalance between
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the formation and scavenging of free radicals leads to
overproduction of electrons. These electrons react with
remnant molecular oxygen, leading to ROS generation
[55]. Abundant ROS could result in cell senescence
through inducing DNA damage [54]. In this study, we
explored whether ROS was the main mediator of MSC
senescence induced by miR-34a overexpression. Results
showed that overexpression of miR-34a increased β-
galactosidase-positive cells as well as ROS production.
When ROS production was reduced by NAC in MSCs,
DNA damage was attenuated and the expression of p16,
p53, and p21 was reduced. These results imply that ROS
has an important role in MSC senescence induced by
miR-34a overexpression and thus may partly explain the
poor survival rate of engrafted MSCs in the infarcted
area.
With rapid development of anti-miRNA chemistries,
even ahead of miRNA mimicry [56], the miR-34a knock-
down by antagomirs or LNA-based anti-miRNAs has
been shown to protect against the deterioration of car-
diac systolic function in mice after acute MI [15]. More-
over, no side effect was reported. Intracoronary infusion
or intramyocardial delivery of MSCs modified with
current developing therapeutics to inhibit the expression
of miR-34a might thus have great advantage in applica-
tion for vascular diseases.
In conclusion, our study reveals that miR-34a is greatly
elevated in MSCs during H/SD, and overexpression of
miR-34a leads to robust apoptosis, while inhibition of
miR-34a significantly increases pressure resistance of
MSCs to H/SD. This apoptosis is highly regulated by
SIRT1/FOXO3a pathway activation, mitochondrial dys-
function, and finally activation of the intrinsic apoptosis
pathway of the CASP3–PARP1 axis. Moreover, our results
show that miR-34a overexpression increases cellular sen-
escence, which may be regulated by ROS production.
However, more work will be needed to determine the role
of SIRT1 and FOXO3a in miR-34a-mediated functions in
myocardial ischemia in vivo and to investigate whether
other signaling pathways such as NOTCH signaling path-
ways, which have been reported to be regulated by miR-34a
[57], are involved in the H/SD process in MSCs.
Conclusions
Our data demonstrate that miR-34a is involved in the
process of H/SD in MSCs, while inhibition of miR-34a
leads to an increase in SIRT1 and a decrease in FOXO3a
protein expression, fewer apoptotic cells, and better via-
bility. Moreover, we found that overexpression of miR-
34a induced senescence of MSCs, which may partly be
abolished by the ROS scavenger NAC. Inhibition of
miR-34a in MSCs would thus be beneficial and could
demonstrate great therapeutic potential in clinical trans-
plantation for vascular disorders.
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